financetom
Business
financetom
/
Business
/
Update: Lightspeed Commerce Shares Fall After Fiscal Q4 Results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Lightspeed Commerce Shares Fall After Fiscal Q4 Results
May 26, 2025 12:48 PM

02:21 PM EDT, 05/22/2025 (MT Newswires) -- (Updates with the latest stock movement in the first paragraph and headline.)

Lightspeed Commerce ( LSPD ) shares were down over 6% in recent Thursday trading following its Q4 results.

Earlier, the company reported fiscal Q4 adjusted net income of $0.10 per diluted share, up from $0.06 a year earlier.

Analysts polled by FactSet expected $0.11.

Revenue for the quarter ended March 31 was $253.4 million, up from $230.2 million a year earlier.

Analysts surveyed by FactSet expected $251.2 million.

The company expects fiscal Q1 revenue of $285 million to $290 million. Analysts expected $286 million.

Revenue for the current fiscal year is projected to grow 10% to 12%, the company said.

Price: 10.06, Change: -0.72, Percent Change: -6.64

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BMO on The Day Ahead in Canada
BMO on The Day Ahead in Canada
Sep 21, 2024
07:52 AM EDT, 09/18/2024 (MT Newswires) -- On the Canadian docket Wednesday at 1:30 p.m. ET, Bank of Montreal (BMO) noted that the Summary of Deliberations from the Bank of Canada's Sept. 4 policy meeting, which saw a third consecutive 25 bp rate cut, will be scoured for any clues on what it would take to prompt more aggressive easing....
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
Organon to buy skin therapy developer Dermavant for up to $1.2 billion
Sep 21, 2024
Sept 18 (Reuters) - Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of $175 million, as well as milestone payments of $75 million and up to $950 million upon achievement of certain commercial milestones. Dermavant's VTAMA psoriasis cream...
GSK Says Trial Evaluating Co-Administration of AREXVY, SHINGRIX Shows Non-Inferior Immune Response
GSK Says Trial Evaluating Co-Administration of AREXVY, SHINGRIX Shows Non-Inferior Immune Response
Sep 21, 2024
08:01 AM EDT, 09/18/2024 (MT Newswires) -- GSK (GSK) said Wednesday that the phase 3 trial evaluating the co-administration of AREXVY with SHINGRIX in adults aged 50 years and older met its primary endpoint. The data showed a non-inferior immune response when both vaccines were co-administered compared with a separate administration, the company said. The company further said the co-administration...
Organon to Acquire Dermavant for $1.2 Billion
Organon to Acquire Dermavant for $1.2 Billion
Sep 21, 2024
08:03 AM EDT, 09/18/2024 (MT Newswires) -- Organon (OGN) said Wednesday it has agreed to acquire Roivant's (ROIV) Dermavant, including its flagship dermatological cream Vtama, for a total consideration of $1.2 billion. Under the deal, Organon will pay $175 million upfront with $75 million as milestone payment after the US Food and Drug Administration approves Vtama's application for treatment of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved